High-dose intravenous immune globulin in the management of severe Guillain-Barré syndrome

Turkish Journal of Pediatrics

Volumn 38, Issue 1, 1996, Pages 119-123

  Baskin, Esra ^a   Türkay, Sadi ^a   Içaǧasioǧlu, Dilara ^a   Tanzer, Fatoş ^a   Cevit, Ömer ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Guillain Barr syndrome; Intravenous immunoglobulin

Indexed keywords

IMMUNOGLOBULIN;

ARTICLE; CASE REPORT; CHILD; DISEASE COURSE; DRUG EFFICACY; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE;

CHILD; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MYELIN SHEATH; PLASMAPHERESIS; POLYRADICULONEUROPATHY; RESPIRATION DISORDERS;

EID: 0030066059     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Hopper AH. The Guillain-Barré syndrome. N Engl J Med 1992; 326: 1130-1136.
2. Rantala H, Cherry JD, Shields WD, Uhari M. Epidemiology of Guillain-Barré syndrome in children: relationship of oral polio vaccine administration to occurrence. J Pediatr 1994; 124: 220-223.
3. Winer JB, Hughes RA, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988; 51: 605-612.
4. Birscoe DM, McMenamin JB, O'Donohoe NV. Prognosis in Guillain-Barré syndrome. Arch Dis Child 1987; 62: 733-735.
5. Keenlyside RA, Schonberger LB, Bregman DJ, Bolyai JZ. Fatal Guillain-Barré syndrome after the national influenza immunization program. Neurology 1980; 30: 929-933.
6. Heaton PA. Severe Guillain-Barré syndrome during childhood responding to intravenous gamma globulin. NZ Med J 1992; 105: 477-478.
7. Shahar E, Murphy EG, Roifman CM. Benefit of intravenously administered immune serum globulin in patients with Gullain-Barré syndrome. J Pediatr 1990; 116: 141-144.
8. Rajah A. The use of high-dose intravenous immunoglobulins in Guillain-Barré syndrome. Anaesthesia 1992; 47: 220-222.
9. Asbury AK, Comblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27: S21-S24.
10. Koski CL, Gratz E, Sutherland J, Mayer RF. Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barré syndrome. Ann Neurol 1986; 19: 573-577.
11. Nyland H, Aorli JA. Guillain-Barré Syndrome: demonstration of antibodies to peripheral nerve tissue. Acta Neurol Scand 1978; 58: 35-43.
12. Consensus Conference. The utility of therapeutic plasmapheresis for neurological disorders. JAMA 1986; 256: 1333-1337.
13. Urtasun M, Lopez de Munain A, Carrera N, Marti-Masso JF. Lopez de Dicastillo G, Mozo C. High-dose intravenous immune globulin in the management of severe Guillain-Barré syndrome. Ann Pharmacother 1992; 26: 32-33.
14. van der Meché FG, Schmitz P. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré study group. N Engl J Med 1992; 326: 1123-1129.
15. Dietrich G, Rossi F, Sultan Y. Kaveri S, Nydegger UE, Kazatchkine MD. IVIG and regulation of auto immunity through the idiotypic network. In: Imbach P (ed). Immunotherapy with Intravenous Immunoglobulins. London: Academic Press; 1991: 3-14.
16. Kleyweg RP, van der Meché FG. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry 1991; 54: 957-960.
17. Irani DN, Cornblath DR, Chaudhry V, Borel C, Hanley DF. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993; 43: 872-875.